



Updates in Penile Cancer

Rafee Talukder, MD Assistant Professor of Medicine Dan L Duncan Cancer Center Baylor College of Medicine MaTOS Genitourinary 3/22/2025

Baylor St. Luke's Medical Center DAN L DUNCAN COMPREHENSIVE CANCER CENTER








Amicuzi U, et al. Diagnostics 2024

MANAGEMENT OF PALPABLE NON-BULKY INGUINAL LYMPH NODES



Neoadjuvant Chemotherapy Prior to ILND or PLND

Preferred Regimen

TIP (paclitaxel, ifosfamide, and cisplatin)

Adjuvant Chemotherapy Following ILND or PLND
Preferred Regimen
• TIP
Other Recommended Regimen
• 5-FU + cisplatin ^{3,4}

First-Line Systemic Therapy for Metastatic/Recurrent Disease
Preferred Regimen • TIP
Other Recommended Regimens • 5-FU + cisplatin
• 5-FU + cisplatin + pembrolizumab followed by pembrolizumab maintenance therapy

• 5 5-FU + cisplatin + pembrolizumab followed by pembrolizumab maintenance therapy
5-FU + carboplatin + pembrolizumab followed by pembrolizumab maintenance therapy

Subsequent-Line Systemic Therapy for Metastatic/Recurrent Disease

Preferred Regimen

Clinical trial


• Pembrolizumab, if unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumor that has progressed following prior treatment and no satisfactory alternative treatment options,^{6,7,8} or if tumor mutational burden-high (TMB-H), TMB ≥10 mut/Mb in patients who have progressed on previously approved lines of therapy⁹

Useful in Certain Circumstances

Paclitaxel


Cetuximab

EAU-ASCO Collaborative Guideline Update for Penile Cancer 2023




Brouwer O et al JCO Oncology Practice 2023

PERICLES: Phase II Trial Atezolizumab +/- XRT for Advanced Penile SCC




Primary objective: 1-year progression free survival ≥ 35%, to exclude 15% (RECIST 1.1) Secondary objectives: OS, response rate, toxicity (NCI-CTCAE V4)





	Arm A, n=18 (%): Atezo + RT	Arm B, n=12 (%): Atezo	Total, n=30 (%)
BOR	8 (44)	2 (17)	10 (33)
Complete response	2 (11)	1 (8.3)	3 (10)
Partial response	6 (33)	1 (8.3)	7 (23)
Stable disease	2 (11)	1 (8.3)	3 (10)

HERCULES: Phase II of Pembrolizumab plus Platinum Chemotherapy as 1st Line Systemic Therapy in Advanced Penile Cancer




Efficacy Outcome	N=33*
Confirmed ORR by investigator	13 (39.4%); (95% Cl, 22.9 - 57.9)
Best overall response by investigator	
Complete Response	1 (3.0%)
Partial Response	12 (36.4%)
Stable Disease	7 (21.2%)
Progressive Disease	11 (33.3%)
Unevaluable**	2 (6.1%)
Confirmed ORR by central review	14 (42.4%); (95% CI, 25.5 – 60.8)
Clinical benefit rate by investigator (CR, PR, SD ≥ 24 weeks)	15 (45.5%); (95% CI, 28.1 – 63.7)





Maluf FC, et al. ASCO Annual Meeting 2024, urotoday.com




Maluf FC, et al. ASCO Annual Meeting 2024, urotoday.com


EPIC-A: Phase II Trial of Cemiplimab plus SOC Followed by Maintenance Cemiplimab in LA/Metastatic Penile Carcinoma

	ELIGIBILITY	INTERVENTION	Primary end point:
APPROVED IN CASE OF	Patient with locally advanced or metastatic carcinoma of the penis: TxN3M0 or TxN2M0 or T3N1M0 or T4anyN or M1 No previous chemotherapy for treatment of penile cancer Histologically-proven squamous cell carcinoma of penis or penile urethra ECOG performance status 0, 1 or 2 Adequate renal, liver and bone marrow function Measurable disease as per RECIST 1.1	4 cycles cisplatin based chemotherapy* IV Q3W + cemiplimab 350mg IV D1 Followed by maintenance with: 30 cycles cemiplimab 350mg IV D1 Q3W 2 years of treatment in total Tumour assessments per RECIST 1.1	Investigator assessed (RECIST 1.1) Clinical Benefit Rate (CBR) at 12 week Secondary Endpoints: Safety CBR at 1, 2, 3 years Overall response rate (ORR) Progression Free survival (PFS) Overall survival (OS) Quality of Life (QoL)
	measurable usease as per ruboro 121.1	*SoC chemotherapy: 1) Cisplatin (80mg/m2) D1 / 5FU (4000mg/m2) D1-4 2) TIP (cisplatin 75mg/m2, paditaxel 175mg/m2 and ifosfamide 3600mg/m2)	Research sites: 11 across UK Period of enrolment: Jan 2022- Dec 2023


Statistical Considerations: A'Hern (2001) study design with α = 0.05 + power (1-β) = 0.8, assuming 25% meeting the clinical end point is poor treatment (p0 0.25) and 50% is a good treatment (p1 = 0.5). Assuming a 10% drop out rate, 29 patients were recruited.

Efficacy outcome	N=29
12 weeks	
Clinical benefit rate (CBR)	62.1% (95%Cl 44.4%, 79.7%)
CR	0
PR	15 (51.7%)
SD	3 (10.3%)
Objective response rate (ORR)	51.7% (95%CI 34.4%, 68.6%)
21 (12+9) weeks	
Clinical benefit rate (CBR)	48.3% (95%CI 31.4%, 65.6%)
CR	1 (3.4%)
PR	12 (41.4%)
SD	1 (3.4%)
Objective response rate (ORR)	44.8% (95%CI 28.4%, 62.4%)






Survival outcomes: PFS and OS



Bahl A, et al. 2025 ASCO Genitourinary Cancers Symposium, urotoday.com

EPIC-B: Phase II Trial of Cemiplimab as First-Line Treatment in Advanced Penile Carcinoma



Bahl A, et al. 2025 ASCO Genitourinary Cancers Symposium, urotoday.com

InPACT (ECOG-EA8314): Phase 3 of ILD Alone or After Chemotherapy with or Without XRT for Patients with Advanced Penile Cancer

